Well Referenced

Tag: biochemical recurrence

Statins Prevent Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy: A Single-center Retrospective Study with a Median Follow-up of 51.20 Months

This 2020 retrospective study evaluated 875 patients post-radical prostatectomy, analyzing the effect of statin use on biochemical recurrence (BCR). Statin use at the time of surgery was reported in 45.7% of patients. Over a median follow-up of 51.2 months, statin users had a significantly reduced risk of BCR (HR 0.599,

Read More »
June 26, 2025 No Comments

Evidence on Statins, Omega-3, and Prostate Cancer: A Narrative Review

This 2022 narrative review examines the associations between statin use, omega-3 fatty acid intake, and prostate cancer (PCa) risk and progression. Statins have been linked to a reduced incidence of advanced PCa and may decrease the risk of biochemical recurrence (BCR) post-treatment. However, their impact on BCR and PCa progression

Read More »
June 26, 2025 No Comments

High-grade Prostate Cancer and Biochemical Recurrence After Radical Prostatectomy Among Men Using 5α-Reductase Inhibitors and Alpha-Blockers

This 2013 cohort study analyzed 1,315 men who underwent radical prostatectomy between 1995 and 2009 to assess the impact of 5α-reductase inhibitors (5-ARIs) and alpha-blockers on tumor grade and biochemical recurrence. Long-term use (≥4 years) of 5-ARIs (finasteride or dutasteride) was associated with a higher proportion of high-grade tumors (Gleason

Read More »
June 26, 2025 No Comments

Safety of Testosterone Therapy in Men with Prostate Cancer

This 2019 review by Morgentaler and Caliber examines the evolving perspective on testosterone therapy (TTh) in men with prostate cancer (PCa). Historically contraindicated, TTh is now considered a viable option for certain patients. The review discusses the “saturation model,” which suggests that prostate tissue’s response to androgens plateaus beyond a

Read More »
June 26, 2025 No Comments

Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy

This observational study evaluated the safety of testosterone replacement therapy (TRT) in 31 men with symptomatic hypogonadism after undergoing brachytherapy for early-stage prostate cancer. Over a median follow-up of 5 years post-brachytherapy, TRT increased median testosterone levels from 188 ng/dL to 498 ng/dL without causing biochemical recurrence. No patients experienced

Read More »
June 26, 2025 No Comments